Licorice extract inhibits the cGAS-STING pathway and protects against non-alcoholic steatohepatitis

Wei Luo, Guang Xu, Zheng Song, Wenqing Mu, Jincai Wen, Siwen Hui, Jia Zhao, Xiaoyan Zhan, Zhaofang Bai, Xiaohe XiaoFrontiers in Pharmacology 2023 · DOI

TL;DR

Licorice extract (LE) effectively mitigates non-alcoholic steatohepatitis (NASH) by specifically inhibiting the cGAS-STING inflammatory pathway. By preventing the oligomerization (clustering) of STING proteins, the extract reduces liver fibrosis and inflammation, performing comparably to synthetic STING inhibitors in mouse models.

What Problem Does This Paper Address?

Non-alcoholic steatohepatitis (NASH) is an aggressive form of fatty liver disease characterized by chronic inflammation and fibrosis (scarring). Despite its rising prevalence alongside obesity and diabetes, there are currently no FDA-approved pharmacological treatments.

Recent research has identified the cGAS-STING pathway as a major culprit in NASH progression. Normally, this pathway detects "danger" signals like viral DNA. However, in a diseased liver, damaged mitochondria release DNA into the cell's cytoplasm, tricking the cGAS-STING pathway into a state of chronic, damaging overactivation. The authors of this paper investigated whether licorice—a staple of traditional medicine known for its liver-protective qualities—could be used to specifically shut down this pathway.

Methods

The researchers employed a multi-tiered approach to validate licorice extract's efficacy:

  • Chemical Characterization: They used Liquid Chromatography-Mass Spectrometry (LC-MS) to identify the primary bioactive compounds in their licorice extract, finding ten major constituents including Glycyrrhizin and Liquiritin.
  • In Vitro Assays: They treated bone marrow-derived macrophages (BMDMs) and human THP-1 cells with the extract before stimulating them with various agonists (like HT-DNA or cGAMP) to trigger the STING pathway.
  • Molecular Analysis: Techniques included Western blotting to check protein phosphorylation, qPCR for gene expression, and a specialized STING oligomerization assay to see if the proteins were physically clustering.
  • In Vivo Modeling: They used a Methionine and Choline-Deficient (MCD) diet to induce NASH in C57BL/6 mice. These mice were treated with LE (500 mg/kg) and/or C-176 (a known synthetic STING inhibitor) to compare therapeutic outcomes.

Datasets

This study did not use large-scale public datasets. Instead, it generated primary experimental data using:

  • Cell Lines: Primary murine BMDMs and human leukemic monocytes (THP-1).
  • Animal Models: 6-8 week old female C57BL/6 mice.
  • Chemical Profiles: A custom LC-MS library used to identify the components of the Glycyrrhiza uralensis extract.

Key Insights and Ideas

  • Pathway Specificity: One of the most interesting findings was that licorice extract is a "surgical" anti-inflammatory. It inhibited the DNA-sensing cGAS-STING pathway but had no effect on the RIG-I-MAVS pathway (which senses RNA). This suggests LE doesn't just cause broad immunosuppression but targets specific inflammatory triggers.
  • The "How" of Inhibition: The researchers discovered that LE works by preventing STING oligomerization. For STING to send a signal to the nucleus to produce inflammatory cytokines, individual STING proteins must cluster together. LE physically interferes with this clustering process.
  • Redundancy with Synthetic Inhibitors: When the researchers combined LE with the synthetic inhibitor C-176, they saw no additive effect. This strongly suggests that licorice extract and C-176 are targeting the exact same molecular mechanism, validating LE as a potent natural alternative to synthetic compounds.

Key Results

  • Reduced Liver Damage: In the NASH mouse model, LE significantly lowered serum levels of ALT and AST (key biomarkers of liver injury).
  • Anti-Fibrotic Effects: Histological staining (Sirius Red and Masson) showed that LE treatment dramatically reduced collagen deposition, effectively slowing the "scarring" of liver tissue.
  • Cytokine Suppression: LE dose-dependently inhibited the expression of pro-inflammatory genes, including Ifnb, Tnf-α, and Il-6, in macrophages stimulated with DNA.
  • Safety Profile: Cell viability assays (CCK-8) confirmed that the extract was non-toxic to macrophages at therapeutic concentrations (below 2.5 mg/mL).

Limitations and Future Work

While the results are promising, the authors and the study's design leave a few stones unturned:

  • The "Magic Bullet" Problem: The study used a whole licorice extract. While they identified ten major compounds, it remains unclear which specific molecule (or combination thereof) is responsible for the STING inhibition.
  • Model Limitations: The MCD diet is a standard model for NASH, but it doesn't perfectly replicate the human metabolic syndrome (MCD mice typically lose weight, whereas human NASH patients are often obese). Testing in a High-Fat Diet (HFD) model would be a logical next step.
  • Clinical Translation: Licorice is generally safe, but chronic high-dose consumption can lead to side effects like hypertension (due to glycyrrhizin). Future work should focus on isolating the most active, least toxic components for human drug development.

Summary updated

Abstract

<b>Background:</b> Inflammation and fibrosis are typical symptoms of non-alcoholic steatohepatitis (NASH), which is one of the most common chronic liver diseases. The cGAS-STING signaling pathway has been implicated in the progression of NASH, and targeting this pathway may represent a new therapeutic strategy. Licorice is a widely used herb with anti-inflammatory and liver-protective properties. In this study, we assessed the effect of licorice extract on the cGAS-STING pathway. <b>Methods:</b> Bone marrow-derived macrophages (BMDMs) were treated with licorice extract and then stimulated with HT-DNA, 2'3'-cGAMP, or other agonists to activate the cGAS-STING pathway. Quantitative real-time PCR and western blot were conducted to analyze whether licorice extract could affect the cGAS-STING pathway. Methionine and choline-deficient diet (MCD) was used to induce NASH in mice, which were treated with licorice extract (500 mg/kg) by gavage and/or c-176 (15 mg/kg) by intraperitoneal injection every 2 days. After 6 weeks of treatment, histological analysis of liver tissue was performed, along with measurements of plasma biochemical parameters. <b>Results:</b> Licorice extract inhibits cGAS-STING pathway activation. Mechanistically, it might function by inhibiting the oligomerization of STING. Treatment with licorice extract reduced inflammation and fibrosis in MCD diet-induced NASH mice models. Furthermore, we found that the therapeutic effect of combination treatment with licorice extract and C-176 (STING inhibitor) on the pathology and fibrosis of MCD diet-induced NASH models was similar to that of licorice extract or C-176 administered alone. <b>Conclusion:</b> Licorice extract can inhibit the cGAS-STING pathway and improve hepatic inflammation and fibrosis in NASH mice models. It strongly suggests that licorice extract may be a candidate therapeutic for NASH.
BibTeX
@inproceedings{luo2023licorice,
  author = {Wei Luo and Guang Xu and Zheng Song and Wenqing Mu and Jincai Wen and Siwen Hui and Jia Zhao and Xiaoyan Zhan and Zhaofang Bai and Xiaohe Xiao},
  title = {{Licorice extract inhibits the cGAS-STING pathway and protects against non-alcoholic steatohepatitis}},
  booktitle = {Frontiers in Pharmacology},
  year = {2023},
  doi = {10.3389/fphar.2023.1160445},
}
Figure